[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:burkitt-lymphoma:bcl2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Burkitt Lymphoma","BCL2 Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.175695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[26],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z"]